# CytomX Therapeutics, Inc. (CTMX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CTMX
## Company Profile
- Ticker: CTMX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 3.37 USD
- Market cap: 687941224.0400001 USD
- Last updated: 2026-08-06
## Business Overview
### Conditionally Activated Biologics
CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates.
### Varsetatug Masetecan
Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY antibody-drug conjugate in Phase 1 development. Its lead indication is advanced colorectal cancer, with dose optimization intended to support a potential registrational study.
### Colorectal-Cancer Strategy
The Phase 1 dose-optimization program in advanced colorectal cancer is intended to select a monotherapy regimen and support a potential registrational study in the late-line setting.
### Combination Development
CytomX is evaluating Varseta-M with bevacizumab and plans a separate chemotherapy-combination study to test whether partner agents can broaden or deepen activity.
### Non-Colorectal Expansion
Additional Phase 1 cohorts will assess Varseta-M in non-colorectal EpCAM-expressing tumors, extending the program beyond its initial indication.
## Why The Stock Is Moving

The latest monitored company update is “CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Varseta-M dose-optimization data in the second half of 2026.
- Initiation of a Phase 1/2 chemotherapy-combination study of Varseta-M in the second half of 2026.
- Initiation of Phase 1 expansion cohorts in non-colorectal indications in the second half of 2026.
- Initial data for Varseta-M plus bevacizumab by the first half of 2027.

## Recent News
- 2026-08-06 20:15 EST — [CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q2-2026-financial-results-and-provides-business-up-f66d0912) — Source: CytomX Therapeutics, Inc.
- 2026-08-03 12:00 EST — [CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-appoints-alejandra-carvajal-as-chief-legal-officer-fcf0cd34) — Source: CytomX Therapeutics, Inc.
- 2026-07-30 12:00 EST — [CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-report-second-quarter-2026-financial-results-on-august-6--97882886) — Source: CytomX Therapeutics, Inc.
- 2026-07-27 12:00 EST — [CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-appointment-of-charles-fuchs-m-d-m-p-h-to-the-boar-83ccd537) — Source: CytomX Therapeutics, Inc.
- 2026-06-03 12:00 EST — [CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer](https://biopharmsignal.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer) — Source: CytomX Therapeutics, Inc.